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Abstract  
AIM: To investigate the relation between bone parameters and the metabolic syndrome criteria, 
before and after the administration of two different natural dietary supplements in middle aged 
working obese Egyptian women suffering from metabolic syndrome (MetS).  
SUBJECTS AND METHODS: Fifty eight middle aged obese female volunteers suffering from 
metabolic syndrome were divided into two groups. During the first period, group (A) consumed a 
low caloric diet and nutritional supplement consisting of doum flour biscuits, while group (B) 
consumed whole meal wheat flour biscuit with the same instructions. During the second period, 
both supplements were omitted. Assessment of blood pressure, relevant anthropometric 
parameters, lipid accumulation product, fasting blood glucose, uric acid, 25 hydroxy vitamin D (25 
(OH) D), parathyroid hormone (PTH) and bone-specific alkaline phosphatase were performed. 
RESULTS: Data showed that although both supplements improved the MetS criteria and the bone 
health parameters, the supplement containing the doum flour proved to be more effective. 
CONCLUSION: These results confirm the benefit of doum in improving bone health parameter [25 
(OH) D/PTH axis] in the MetS patients, beside the MetS criteria. So, we can conclude that natural 
effective supplements lead towards the optimization of biochemical parameters in favor of a healthy 
outcome.  
 
 
Introduction 
 
The metabolic syndrome (MetS) is a cluster of 
risk factors, including abdominal obesity, 
hypertension, high blood glucose and triglycerides 
levels and low serum high density lipoprotein- 
cholesterol (HDL-C) concentration. The MetS might 
cause the development of several health problems. 
High levels of blood glucose are linked to many 
harmful changes in the body, including; changes in 
the kidneys' ability to remove salt, leading to 
hypertension, heart disease and stroke; an increased 
risk of blood clot formation, which can block arteries 
and cause heart attacks and strokes. Uncontrolled 
diabetes is also associated with complications on the 
eyes, nerves, and kidneys [1]. 
The WHO defined the MetS as glucose 
intolerance, impaired glucose tolerance (IGT) or 
diabetes mellitus (DM), together with two or more of 
these components: hypertension, raised plasma 
triglycerides (≥ 150 mg/dl) and/or low HDL-C (< 35 
mg/dl in men and <39 mg/dl in women), central 
obesity that means waist circumference (WC) ≥ 
102cm (male), ≥ 88 cm (female), waist/hip ratio 
(WHR) > 0.90 in men and > 0.85 in women and/or 
body mass index (BMI) > 30 kg/m
2 
, microalbuminuria, 
i.e., urinary albumin excretion rate ≥ 20 μg/minute or 
albumin/creatinine ratio ≥ 30 μg/mg, and abnormal 
uric acid metabolism (increased plasma uric acid 
concentration and/or decreased renal uric acid 
clearance) [2]. 
Vitamin D (VD) is a steroid hormone that is 
essential for the intestinal absorption of calcium and 
phosphorus, and the building of strong bones [3]. In 
the liver, the vitamin is hydroxylated to 25-
hydroxyvitamin D (25 (OH) D), the major circulating 
metabolite of vitamin D. Although 1,25-dihydroxy 
vitamin D (1,25- (OH)2 D) portrays the biological active 
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form of vitamin D, which is synthesized in the kidney, 
it is widely accepted that the measurement of 
circulating 25 (OH) D provides a better information 
with respect to the patients' vitamin D status and 
allows its use in the diagnosis of hypovitaminosis [4]. 
Both of VD and parathyroid hormone (PTH) 
are responsible for maintaining extracellular calcium 
homeostasis [5]. PTH is secreted in response to low-
circulating calcium concentrations. In addition to its 
essential role in bone health, VD has multiple 
extraskeletal beneficial effects as hormone regulation, 
inflammation reduction, and the optimal functioning of 
both the nervous and the immune systems [6]. 
Several studies in adults suggest a link between VD 
deficiency and cardiovascular disease risk [7], 
diabetes or glycosylated haemoglobin (HbA1c) levels 
[8], hypertension [9], and dyslipidemia [10]. The VD 
receptors are present on pancreatic β cells and 
insulin-sensitive tissues including skeletal muscle 
tissues. Reduced circulating 25 (OH) D concentrations 
were found to be associated with higher fasting blood 
glucose level, reduced insulin sensitivity and 
increased risk of type 2 diabetes and metabolic 
syndrome [11].  
Bone specific alkaline phosphatase (BAP), 
the bone-specific isoform of alkaline phosphatase, is a 
glycoprotein that is found on the surface of 
osteoblasts, and reflects the biosynthetic activity of 
these bone-forming cells. BAP has been shown to be 
a sensitive and reliable indicator of bone metabolism 
[12]. Normal bone is constantly undergoing 
remodeling in which bone degradation or resorption is 
balanced by bone formation a process necessary for 
maintaining bone health. If the rate of resorption 
exceeds the rate of formation, the resulting bone loss 
can lead to osteoporosis and, consequently, a higher 
susceptibility to fractures [12, 13]. 
The aim of this study was to investigate the 
relation between the important bone health 
parameters and the metabolic syndrome criteria, and 
to verify the effect of using two dietary supplements; 
composed of doum in the first and whole wheat in the 
other, in conjunction with a balanced hypocaloric 
regimen in improving the MetS criteria, the 25 
(OH)D/PTH axis and serum uric acid level in middle 
aged working obese women suffering from the 
metabolic syndrome. 
 
 
Material and Methods 
Materials 
Wheat grains (Giza 168) was purchased from 
Wheat Research Department, Field Research 
Institute, Agriculture Research Center, Giza, Egypt. 
Dry doum flour was obtained from local herbal shop, 
Dokki, Egypt. Skimmed milk, sucrose, shortening, 
corn oil, baking powder, emulsifier, vanilla, bread 
improver and eggs were purchased from the local 
market, Dokki, Egypt. 
 
Preparation of flour 
Wheat grains (Giza 168) were cleaned, 
tempered (15% moisture) and milled (Quadrumat 
Junior flour mill) to 100 % extraction flour. Whole meal 
wheat flour 100 % extraction (WMWF) was well 
blended with doum flour (DF) to produce individual 
mixture containing 30% replacement level. All 
samples were stored in airtight containers and kept at 
5-7ºC until required. 
 
Preparation and evaluation of biscuits 
Two types of biscuits recipes were prepared 
by using DF at 30% level with WMWF (Biscuit 1), or 
using WMWF alone at 100% level (Biscuit 2); to be 
mixed with other ingredients according to table (1). 
Then 14.7 ml of dextrose solution (5.93%) and a 
suitable amount of water were added according to 
AACC [14]. These formulas were baked in a special 
oven at 200 °C for about 15 minutes.  
Table 1: Composition of mixtures used in the manufacture of 
biscuits 
Ingredients (in grams)                                   30% DF Biscuit (1)             WMWF  Biscuit (2) 
Whole meal wheat flour (WMWF)                                 70                               100 
Doum flour (DF)                                                             30                                 - 
Corn oil                                                                             5                                 5 
Baking powder                                                                 1.1                              1.1 
Salt                                                                                   1.0                              1.0 
Emulsifier                                                                          1.0                             1.0 
Skimmed  milk                                                                   5                               5 
 
Subjects 
Fifty eight obese female volunteers suffering 
from metabolic syndrome were enrolled in a program 
for losing weight at the nutrition department, NRC, 
Dokki, Gizza, Egypt. An informed consent was 
obtained from each participant to be included in the 
study. The protocol of the study was approved by the 
NRC Ethics committee.  
Selection of the patients was based on the 
presence of at least three of the following five criteria 
of MetS according to the definition done by National 
Cholesterol Education Program Adult Treatment 
Panel III (NCEP ATP III) [15]: (1) elevated waist 
circumference (≥88 cm); (2) elevated blood pressure 
(≥130/85 mm Hg) or the use of medication for 
hypertension; (3) elevated fasting blood glucose: ≥100 
mg/dl or the use of medication for hyperglycemia; (4) 
elevated serum triglycerides (TG) (≥ 150 mg/dl); (5) 
reduced serum HDL-C (< 50 mg/dL). 
Subjects were middle aged working obese 
females, who had similar socioeconomic status and 
exposure to sunlight. None of the subjects had a 
history of hepatic or renal disorders, and none were 
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taking any vitamin or mineral supplements, nor were 
on weight loss or exercise programs before starting 
the study. A detailed sheet for the diet regimen was 
given at the first visit to each patient; weekly follow up 
was performed to assure adequate compliance. 
The study was divided into two phases, each 
one lasted for 4 weeks; the participants were divided 
into two groups: 34 subjects (group A), and 24 
subjects (group B). During the 1
st
 phase; group (A) 
were consumed a low caloric diet (≈ 1000 – 1200 
Kcal/ day) and a nutritional supplement consisting of 
the doum biscuits (Biscuit 1) that was consumed as 2 
biscuits at breakfast and 1 biscuit at dinner, each 
doum biscuit weighed 20 g and contained 30% DF, 
70% WMWF. Group (B) consumed the same diet in 
addition to the supplement consisting of the whole 
wheat flour biscuit (Biscuit 2) with the same 
instructions. During the 2
nd
 phase, both groups were 
following only the low caloric balanced diet. 
 
Anthropometric Parameters and Blood 
Pressure Measurements 
Relevant anthropometric measurements were 
reported including height, weight and minimal waist 
circumference (MWC) at the end of expiration, and hip 
circumference using the standard method [16]. Body 
mass index (BMI) and waist hip ratio (WHR) were 
calculated (weight kg/ height² meter, and waist 
circumference cm/ hip circumference cm 
respectively). Using Geratherm Body Fitness (B-
5010), Germany, percent body fat mass (% BFM) and 
fat free mass (FFM) were assessed. Blood pressure 
was measured 3 times and the mean was 
recorded.The lipid accumulation product (LAP) was 
computed using MWC (in cm) and fasting triglycerides 
level (in mmol/l): [(WC – 65) × TG] (men) and [(WC – 
58) × TG] (women)] [17]. 
 
Blood Sampling and Biochemical Analysis 
Blood samples were drawn in the morning 
from all subjects after ten hours fasting. The blood 
samples were allowed to clot, centrifuged and sera 
were separated. Fasting blood glucose (FBG) was 
determined in fresh sera using the oxide peroxidase 
method [18]. The remaining sera were divided into 
aliquots and stored at –70
o
C until used for further 
analysis. The fasting triglycerides were estimated 
enzymatically by triglycerides proceed No 2100 
Stanbio Liquicolor [19]. High density lipoprotein 
cholesterol (HDL-C) was determined by HDL-C 
proceed No 0599 Stanio Liquicolor [20]. Serum 25 
hydroxy vitamin D (25 (OH) D) was assessed by 
Vitamin D direct ELISA kit (EIA-4696) DRG ® 
International, Inc. USA [21]. Serum parathyroid 
hormone (PTH) was measured by human PTH ELISA 
kit (hPTH-EASIA) KAP1481 DIA source 
ImmunoAssays S.A. - Rue de l'Industrie, 8 - B-1400 
Nivelle – Belgium [22]. BAP EIA Kit an enzyme 
immunoassay for the quantitation of bone-specific 
alkaline phosphatase (BAP) in human serum provided 
by MicroVue™ 8012 –Quidel Corporation 10165 
McKellar Court, San Diego, CA 92121 USA [23]. 
Serum uric acid was determined by Uric Acid 
Liquicolor Test Enzymatic supplied by Stanbio [24]. 
All the above mentioned parameters were 
performed at the start of the study (1
st
 assessment), 
by the end of phase 1 (2
nd
 assessment) and lastly by 
the end of the study (3
rd
 assessment). 
 
Dietary Recalls 
Collecting detailed basal data about nutritional 
habits and intake through 24hr recalls was recorded. 
Analysis of food items was performed using World 
Food Dietary Assessment System (WFDAS) 1995, 
USA, and University of California. 
 
Statistical Analysis 
Statistical analyses were performed using 
SPSS window software version 17.0 (SPSS Inc. 
Chicago, IL, USA, 2008). Data were expressed as 
mean± SE. Two tailed Student's t-test was used to 
compare between the data at the different phases. P 
values <0.05 were considered statistically significant. 
Pearson’s correlation coefficient (r) was calculated to 
find the associations between different variables.  
 
 
Results  
 
Data presented in Table 2 showed the 
composition of the prepared biscuits. Protein, fat and 
total carbohydrate contents were lower in biscuits 
substituted with DF compared to the biscuit prepared 
from WMWF alone. Addition of DF to WMWF caused 
changes in the mineral contents of biscuits. 
Polyphenol content of the DF biscuit was more than of 
the WMWF biscuit. 
Table 2: Nutrient contents of the two types of the biscuits 
Constituents 30% DF Biscuit WMWF Biscuit (0% DF) 
Moisture (%) 
Protein (g)  
Fat (g) 
Carbohydrates (g)  
Crude fiber (g) 
Total Ash (g)  
Phosphorus (mg) 
Potassium (mg)  
Calcium (mg) 
Magnesium (mg) 
Sodium (mg) 
Iron (mg)   
Polyphenols (mg)  
4.80 ± 0.12 
11.75 ± 0.34 
6.50 ± 0.15 
72.45 ± 0.69 
5.60 ± 0.40 
3.70 ± 0.25 
305 ± 0.11 
290 ± 0.21 
70 ± 0.01 
84 ± 0.03 
420 ± 0.13 
2.8 ± 0.01 
164.3 
3.82± 0.22 
13.5 ± 0.18 
7.25 ± 0.35 
75.62 ± 0.77 
1.85 ± 0.02 
1.78 ± 0.12 
187± 0.12 
115± 0.09 
40± 0.03 
115±0.08 
650± 0.11 
3.5±0.03 
110.0 
Values are means of three determinations ± SE. 
Table 3 & 4 showed a comparison between 
the different macronutrients and micronutrients and 
the percent caloric distribution of the habitual diet of 
Basic Science 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
   4                                                                                                                                                                                                                        http://www.mjms.mk/ 
http://www.id-press.eu/mjms/ 
 
the whole sample before starting the regimen and of 
the two types of regimen.  
Table 3: Mean ± SE of the daily nutrients intake of habitual diet 
in the whole sample, and of the two different regimens 
Nutrients Habitual diet Regimen with 
30%DF Biscuits 
Regimen with 
WMWF Biscuits 
Energy (kcal) 
Protein (g)                   
Carbohydrate (g)  
Fat (g) 
Calcium (mg) 
Iron (mg)   
Sodium (mg) 
Potassium (mg)     
2230.02 ± 9.18 
89.74 ± 4.59 
265.90 ± 12.88 
87.19 ± 4.81 
765.37 ± 6.20 
16.69 ± 0.97 
3919.55 ± 2.35 
2871.25 ± 5.56 
1127.18 ± 7.21 
1127.18 ± 7.21 
142.33 ± 6.22 
34.421 ± 2.14 
537.21 ± 5.22 
12.82 ± 1.42 
1985.40 ± 3.50 
2947.14 ± 3.43 
1143.39 ± 4.16 
58.02 ± 2.33 
144.0 ± 6.28 
34.87 ± 1.64 
519.21 ± 3.25 
13.24 ± 0.12 
2123.46 ± 3.47 
2842.14 ± 3.18 
 
The data showed the balanced and healthy 
distribution of the macronutrients in the two regimens 
compared to the habitual diet of the patients. 
Table 4: Percent caloric intake from the three main 
macronutrients of the habitual diet in the whole sample, and of 
the two different regimens 
 Habitual diet Regimen with 
30% DF 
Regimen with 
WMWF Biscuits 
Total Calories 
% Calories from protein 
% Calories from carbohydrate     
% Calories from fat                                                                                      
2230.02 
16.1 
47.7 
35.2 
1127.2 
20.2 
50.4 
27.5
1143.4 
20.3 
50.4 
27.4 
 
Table 5 showed that at the end of 1
st
 phase of 
the study (2
nd
 assessment), there was a highly 
significant (p < 0.01) decrease of % body fat mass 
(%BFM), mean minimal waist circumference (MWC) 
and waist hip ratio (WHR) in both groups, but % 
decrease was greater in the doum group (group A) 
compared with the whole wheat group (group B). At 
the end of the 2
nd 
phase of the study (3
rd
 assessment), 
patients were on the low caloric diet alone, % BFM, 
FFM, MWC and WHR showed highly significant 
decrease (p < 0.01) in group (A), while in group (B) 
only MWC was significantly decreased (p < 0.05). 
SBP, DBP and LAP of both groups decreased 
significantly by the end of 1
st
 phase (2
nd
 assessment), 
only DBP of group B decreased significantly at the 
end of 2
nd
 phase (3
rd
 assessment), while other reading 
values decreased numerically except LAP of group B 
which increased numerically.  
At the 2
nd
 assessment the mean levels of the 
fasting blood glucose (FBG) and triglyceride (TG) 
decreased significantly (p 0.05 - < 0.01), while the 
high density lipoprotein–cholesterol (HDL-C) 
concentration increased significantly, in both groups. 
The 3
rd
 assessment showed elevation of both FBG 
and TG, and reduction of the HDL-C levels. 
Table 6: Mean ± SE of the biochemical parameters of the two 
groups at the basal and the two phases of the study 
Parameters 
Group A (no.= 34 Subjects) Group B (no.=24 Subjects) 
1stassess-
ment 
2ndassess-
ment 
3rdassess-
ment 
1st assess-
ment 
2ndassess-
ment 
3rdassess-
ment 
25 (OH) D 
(nmol/L) 
51.9 ±2.2 56.2 ±2.3**a 57.6 ±3.3*b 48.1 ±1.7 51.3 ±1.8*a 53.8 ±1.7*b 
% change +8.3**a +2.5*b - +6.7*a +4.9*b 
PTH (pg/ml) 81.2 ±2.8 77.3±2.5**a 
80.6 ±2.5 
 
84.2 ±3.2 
 
80.8 ±2.9*a 
81.7 ±2.7 
 
% change -4.8**a +4.3 - -4.04 +1.11 
BAP (µg/L) 25.4 ±1.3 24.3±1.4 24.4 ±1.4 25.2 ±1.3 23.0 ±1.3*a 23.4 ±1.3 
% change -4.3 +0.4 - -8.7*a +1.7 
Uric acid 
(mg/dl) 
5.9 ±0.2 5.1 ±0.1**a 4.9 ±0.1 5.6 ±0.2 4.8 ±0.2**a 4.5 ±0.2 
% change -13.6**a -3.9 - -14.3**a -4.2 
25 (OH) D: 25 hydroxy vitamin D, PTH: Parathyroid hormone, BAP: Bone specific alkaline 
phosphatase. 
*
P value < 0.05
 
**P value < 0.01; a: 1
st
 assessment vs. 2
nd
 assessment,       
b: 2
nd
 assessment vs. 3
rd
 assessment.             
 
The biochemical parameters of the 
participants at the three different assessments are 
shown in Table 6. At the 1
st
 assessment, 25 (OH) D 
level was in the range considered to be deficient (≤ 50 
nmol/L) or insufficient (≤ 75 nmol/L), however the 
mean PTH level was higher than the normal range in 
both groups (normal PTH ≤ 65 pg/ml).  
 
Table 5: The effect of the two dietary supplements on clinical and anthropometric parameters, and metabolic syndrome criteria 
Parameters 
Group A (no.= 34 Subjects) Group B (no.= 24 Subjects) 
1
st
assessment 2
nd
assessment 3
rd
assessment 1
st
assessment 2
nd
assessment 3
rd
assessment 
Age(yr) 50.3±0.81   46.9±0.87   
SBP (mmHg) 137.7±1.91 131.9±2.40
*a 
128.4±2.85 138.2±3.27 125.8±3.04
**a 
123.6±2.51 
% change -4.2 -2.7 - -8.9 -1.7 
DBP (mmHg) 91.3±1.42 86.4±1.17
**a 
83.9±1.04 89.0±1.75 84.6±1.44
**a 
82.3±1.64
*b 
% change -5.4 -2.9 - -4.9 -2.7 
BMI (kg/m
2
)
 
38.8±1.24 37.6±1.23
**a 
36.6±1.44
**b 
38.2±1.33 37.1±1.22
**a 
36.8±1.27 
% change -3.9 -2.7 - -2.9 -0.8 
Body fat mass% 45.37 ±2.29 43.14 ±2.29
xxa 
41.17 ±2.67
**b 
44.77 ±2.51 42.72 ±2.33
**a 
42.23 ±2.43 
% change -4.9 -4.6 - -4.6 -1.1 
Fat free mass 51.38 ±1.07 50.61 ±1.08
**a 
49.68 ±1.22
xxb 
51.77 ±1.33 50.89 ±1.29
**a 
50.87 ±1.37 
% change -1.5 -1.8 - -1.7 -0.03 
MWC (cm) 101.9 ±2.12 97.0 ±2.00
**a 
92.9 ±2.55
**b 
96.1 ±2.05 92.1 ±1.99
**a 
90.7 ±1.88
*b 
% change -4.8 -4.2 - -4.2 -1.5 
WHR (cm/cm) 0.83 ±0.01 0.81 ±0.01
**a 
0.78 ±0.01
**b 
0.79 ±0.01 0.78 ±0.01
**a 
0.76 ±0.01 
% change -2.4 -3.7 - -1.3 -2.6 
Hip (cm) 123.6 ±2.12 120.0 ±1.98
**a
 118.2 ±2.45
**b
 122.1 ±2.33 118.8 ±2.27
**a
 116.9 ±2.21
**b
 
% change -2.9 -1.5 - -2.7 -1.6 
BMR 2406 2368 2332 2402 2368 2359 
Lipid accumulation product 8316.0 ± 880.46 5811.8 ±721.67
**a 
5250.9 ±698.79
 
5168.8 ±546.81 3638.9 ±287.28
xxa 
3904.28 ±269.83 
% change -30.1 -9.7 - -29.6 +7.3 
FBG (mg/ dl) 128.9±7.14 106.9±6.06
**a 
111.3±5.67 106.3±7.13 89.5±3.10
*a 
92.7±2.16 
% change -17.1 4.2  -15.8 3.6 
TG (mg/ dl) 188.5±13.68 149.0±11.68
**a 
156.2±13.88 136.0±8.64 107.1±6.71
**a 
122.6±8.51
*b 
% change -20.5 4.2  -21.3 14.5 
HDL-C (mg/ dl) 47.1±1.06
 
59.6±1.44
**a 
55.5±2.45
*b 
43.9±2.01 54.2±2.05
**a 
49.5±1.82
*b 
% change 26.5 -6.9  23.5 -8.7 
 
SBP: Systolic blood pressure, DBP: Diastolic blood pressure, BMI: Body mass index, MWC:  Minimal waist circumference, WHR: waist hip ratio, BMR: Basal metabolic rate, FBG: Fasting 
blood glucose, TG: Triglycerides, HDL-C: High density lipoprotein cholesterol. 
*
P value < 0.05,
 **
 P value < 0.01   a: 1
st
 assessment vs. 2
nd
 assessment    b: 2
nd
 assessment vs. 3
rd
 
assessment    
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After dietary supplement consumption, 25 
(OH) D was significantly increased in both groups (p < 
0.01 in group A, p < 0.05 in group B), while the mean 
level of the PTH was significantly decreased in both 
groups. At the 3
rd
 assessment, 25 (OH) D increased 
significantly in both groups (p < 0.05), while the mean 
levels of the PTH were numerically increased. The 
mean levels of the BAP were elevated at the 1
st
 
assessment in both groups and decreased 
numerically with weight loss in group (A), but 
significantly decreased in group (B) at p < 0.05. In the 
2
nd
 phase of the studied BAP levels increased without 
showed statistical significance. Uric acid levels were 
significantly decreased in both groups after dietary 
supplement but the % change of decrease was 
greater in group (B) as compared with group (A). 
Table 7 showed the correlation coefficient 
between the different studied parameters. The most 
important significant negative correlation was found 
between PTH and 25 (OH) D in both groups. The 25 
(OH) D showed significant positive correlation with 
HDL-C in group (A), and negative correlation with 
DBP and TG in group (B). 
There was a significant positive correlation 
between PTH and BMI, MWC and TG in group (A), 
while in group (B), PTH was significantly positively 
correlated with SBP, DBP and BAP. FBG and BAP 
were positively correlated in group B. Non significant 
negative correlation was found between 25 (OH) D 
and BAP levels. 
Table 7: Correlation coefficient between the bone health 
parameters and the metabolic syndrome criteria at the basal 
and the two phases of the study 
 BMI MWC SBP DBP FBG TG HDL-C 25 (OH) D BAP 
Group A  Parathyroid hormone (pg/ml) 
1
st
 assessment 0.498
**
 0.313 0.069 0.062 0.202 0.452
**
 0.135 -0.601
**
 0.184 
2
nd
 assessment 0.429
*
 0.298 0.142 0.286 0.179 0.287 -0.360
*
 -0.691
**
 0.314 
3
rd
 assessment 0.564
**
 0.469
**
 0.032 0.199 0.318 0.604
**
 0.003 -0.709
**
 0.118 
Group B  Parathyroid hormone (pg/ml) 
1
st
 assessment 0.075 0.201 0.439
*
 0.487
*
 0.299 0.359 0.211 -0.519
**
 0.459
*
 
2
nd
 assessment 0.198 0.247 0.446
*
 0.652
**
 0.126 0.104 0.204 -0.719
**
 0.145 
3
rd
 assessment 0.114 0.291 0.678
**
 0.617** 0.116 0.292 -0.067 -0.647
**
 0.094 
Group A  25 hydroxy vitamin D (nmol/L) 
1
st
 assessment -0.196 -0.103 0.283 0.236 -0.247 -0.241 0.185 - -0.211 
2
nd
 assessment -0.208 -0.106 -0.124 0.163 -0.286 -0.113 0.543
**
 - -0.041 
3
rd
 assessment -0.207 -0.123 0.033 -0.024 -0.141 -0.320 0.210 - -0.126 
Group B  25 hydroxy vitamin D (nmol/L) 
1
st
 assessment 0.302 0.087 0.032 -0.134 0.351 0.146 0.340 - 0.053 
2
nd
 assessment -0.298 -0.340 -0.242 -0.577
**
 0.081 -0.549
**
 0.071 - -0.162 
3
rd
 assessment -0.214 -0.289 -0.309 -0.487
*
 -0.196 -0.502
*
 0.046 -     -0.185 
Group A  Bone specific alkaline phosphatase (µg/L) 
1
st
 assessment 0.094 0.005 0.321 0.369
*
 0.154 0.006 -0.290 -0.211 - 
2
nd
 assessment 0.210 0.092 0.175 0.014 0.062 0.088 -0.249 -0.041 - 
3
rd
 assessment 0.146 0.119 0.036 0.185 0.241 0.291 -0.050 -0.126 - 
Group B  Bone specific alkaline phosphatase (µg/L) 
1
st
 assessment 0.070 0.089 0.283 0.428
*
 0.153 0.231 0.130 0.053 - 
2
nd
 assessment 0.115 0.076 0.310 0.210 0.410
*
 0.066 0.302 -0.162 - 
3
rd
 assessment 0.238 0.168 0.237 0.115 -0.157 0.072  0.176 -0.185 - 
 
BMI: Body mass index, MWC: Minimal waist circumference, SBP: Systolic blood pressure, 
DBP: Diastolic blood pressure, FBG: Fasting blood glucose, TG: Triglycerides, HDL-C: 
High density lipoprotein cholesterol. Numbers presented in this table are the value of r 
=correlation coefficient. *Correlation is significant at the 0.05 level (2-tailed) **correlation is 
significant at the 0.01 level (2- tailed). 
 
 
Discussion 
The tenet "Let food be the medicine and 
medicine be the food," espoused by Hippocrates 
nearly 2,500 years ago, is receiving renewed interest. 
In particular, there has been an explosion of 
consumer interest in the health enhancing role of 
specific foods or physiologically-active food 
components, so-called functional foods [25]. 
Functional foods either from plant or animal sources 
may enhance health [26]. 
Doum palm (Hyphaene thebaica) is a desert 
palm native to Egypt. It is known in Egypt as the doum 
or gingerbread palm which grows to a height of 6 or 9 
m and usually has forked stems with fan shaped 
leaves, 65–75 cm long. It is listed as one of the useful 
plants of the world [27].  
The data in this study revealed that patients 
who consumed biscuits made from the 30% DF and 
biscuit with WMWF showed significant decreases in 
their anthropometric parameters. Furthermore, 
chemical analysis results revealed that adding 30% 
DF to the WMWF biscuits increased the fiber and the 
polyphenols contents of the biscuits. The influence of 
these components was especially observed on the 
BMI and MWC which showed the higher percent 
decrease among all the anthropometric parameters in 
both groups, yet group (A) who consumed 30% DF 
biscuits showed the higher decrease when compared 
to group (B). In this context visceral obesity may 
represent a clinical intermediate phenotype reflecting 
the relative inability of subcutaneous adipose tissue to 
act as a protective metabolic sink for the clearance 
and storage of the extra energy derived from dietary 
triglycerides, leading to ectopic fat deposition in 
visceral adipose depots [28]. 
The results of this study demonstrated the 
effect of the two dietary supplements on LAP and 
blood pressure measurements more than the effect of 
low caloric diet alone. In view of the role of central 
obesity and dyslipidemia in the atherosclerotic 
process, an alternative continuous index of lipid over 
accumulation, LAP has been proposed; LAP is a 
simple indicator that requires only the determination of 
circulating triglycerides and measurement of MWC. 
The MWC is unable to distinguish between visceral 
adipose tissue and subcutaneous adipose tissue. 
Visceral adiposity is more strongly associated with 
cardiometabolic risks compared with subcutaneous 
adipose tissue [17]. Visceral adipose tissue 
adipocytes have a higher rate of lipolysis and also 
produce more adipocytokines, such as interleukin-6 
and plasminogen activator inhibitor-1 [29]. Therefore, 
it is important to include a routinely applicable 
indicator for evaluation of visceral adiposity. 
Triglycerides have been reported as a significant 
correlate with visceral adipose tissue in healthy men, 
even after controlling for abdominal subcutaneous 
adipose tissue. LAP will increase as more lipids are 
deposited in non-adipose “ectopic” tissues such as the 
liver, blood vessels, pancreas, kidneys and skeletal 
muscles, where they may adversely affect cellular 
function and interfere with cardiovascular regulation 
[17]. 
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The baseline data demonstrated 25 (OH) D 
deficiencies. Dietary intervention improved the vitamin 
level that coincided with weight reduction especially 
with decreased BMI, %BFM, FFM, and WHR. The 
basis of low 25 (OH) D concentrations in obesity is still 
under debate and could be the result of several 
mechanisms. One hypothesis is that the high content 
of body fat acts as a reservoir for lipid soluble VD and 
increases its sequestration, thus determining its low 
bioavailability [30]. In obese subjects, not only fat 
mass is increased but also lean body mass, as an 
adaptive response to greater body weight. In animal 
studies it has been shown that VD was stored 33% in 
fat and 20% in muscle [31], suggesting that muscle 
could be also another reservoir of VD in humans. 
Another hypothesis is that the synthesis of 25 (OH) D 
by the liver may occur at a lower rate in obese 
subjects due to hepatic steatosis [32]. An alternative 
explanation is that higher leptin and interleukin 6 
circulating levels, mostly secreted by adipose tissue, 
and may have inhibitory effects on 25 (OH) D 
syntheses via their receptors [33].  
Several weight loss/diet interventions have 
measured VD before and after weight loss, and 
observed that 10% loss in weight and % BFM, and 9 
% reduction in MWC resulted in a greater increase in 
25 (OH) D levels (about 34 %). Yet the study 
suggested there might be a threshold of weight loss or 
time needed to see a significant increase in 25 (OH) D 
levels. However, other researchers found a significant 
seasonal variation in 25 (OH) D concentrations than 
changes in weight or fat mass. The researchers found 
a significant season by time interaction, indicating that 
the change in 25 (OH) D levels was dependent on 
season during enrolment and suggested seasonal 
variation may have had a greater impact on 25 (OH) D 
than changes in weight or fat mass [34].  
The PTH concentrations were elevated in our 
study in concordance with several previous studies in 
adults. It has long been accepted that both depressed 
25-(OH) D and reactive rises in PTH were 
consequences of obesity. It is also plausible that 
depressed 25 (OH) D and elevated PTH levels might 
also play a role in the development of obesity as there 
are known physiological mechanisms through which 
depressed 25 (OH) D and/or PTH elevations promote 
the accumulation of adipose tissue [35]. VD has been 
postulated to mediate the effect of PTH on 
intracellular calcium influx as a mechanism for 
increased fat storage [36]. In this study, the mean 
BAP levels were elevated which was associated with 
the detected PTH elevation. However previous studies 
also have shown that postmenopausal women have 
higher BAP levels than do premenopausal subjects 
and that this may be due to the increased bone loss 
observed after menopause [37]. 
Previous studies have showen a close 
relation between hyperuricemia and metabolic 
syndrome in adults [38]. Although hyperuricemia is 
well recognized as a risk factor for atherosclerotic 
diseases such as myocardial infarction and stroke, the 
independence of this association from other 
confounding factors has remained controversial. This 
is mostly because serum uric acid is associated with 
other cardiovascular risk factors, such as 
hypertension and dyslipidemia [39]. However, 
Makovey et al. [40], reported that higher serum uric 
acid levels appear to be protective for bone loss in 
peri- and postmenopausal women as being a strong 
endogenous antioxidant, and this relationship is not 
affected by changes in body composition measures. 
Data of this study showed that the serum uric acid 
concentration among the patients at the baseline 
assessment was at the high normal range, and then a 
significant reduction was observed after the dietary 
intervention, less reduction was detected after 
stopping the supplement, and that is where the use of 
the supplements that contain antioxidant ingredients, 
is likely to have led to a lack of the body's need to 
raise the proportion of uric acid as an antioxidant, to 
avoid the other pathological diseases caused by the 
high uric acid concentration as already mentioned. 
In conclusion, using a dietary therapy 
composed of a hypocaloric balanced regimen and a 
supplement formulae made from doum flour and 
whole meal wheat flour, resulted in improving the 
25(OH) D/ PTH axis by increasing the level of 25(OH) 
D and decreased parathyroid hormone, which lead to 
normalization of the bone specific alkaline 
phosphatase, that can promote and protect bone 
health. Decreasing uric acid and lipid accumulation 
product is an additional benefit which could potentially 
support metabolic syndrome obese patients. 
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